Inspira Technologies Deploys ART100 in Top-10 New York Academic Medical Center
Inspira Technologies has initiated a structured commercial evaluation of its FDA-cleared ART100 system at a New York academic medical center ranked among the state’s top 10. This deployment expands the company’s footprint in Tier-1 U.S. hospitals and aims to establish protocols for broader institutional adoption.
1. Deployment and Evaluation
Inspira Technologies has integrated its ART100 life-support and diagnostic system into the clinical workflow of a leading New York academic medical center, initiating a structured evaluation to define clinical protocols. The institution serves a large patient population and ranks among New York State’s top 10 hospitals, underscoring the system’s clinical credibility.
2. Strategic Expansion
This deployment marks a key step in Inspira’s U.S. commercial strategy, building on prior FDA clearance and installations at other major healthcare facilities. By targeting Tier-1 hospitals, the company aims to convert high-profile evaluations into a sustainable commercial pipeline and strengthen its presence in critical U.S. markets.
3. Growth and Future Prospects
Following ART100’s rollout in New York, Inspira plans to leverage evaluation outcomes to drive adoption at additional academic centers and community hospitals. The company is also advancing its next-generation ART500 system and continuous monitoring HYLA™ platform to broaden its suite of FDA-cleared life-support solutions.